Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS TrialGlobeNewsWire • 10/15/20
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for PatientsGlobeNewsWire • 08/28/20
All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to BuyZacks Investment Research • 08/11/20
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial SarcomaGlobeNewsWire • 07/23/20
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020GlobeNewsWire • 07/22/20
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?Zacks Investment Research • 06/17/20
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong IndustryZacks Investment Research • 06/17/20
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary SharesGlobeNewsWire • 06/04/20
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?Zacks Investment Research • 06/02/20
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesGlobeNewsWire • 06/02/20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary SharesGlobeNewsWire • 06/01/20
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ CancerGlobeNewsWire • 05/29/20